Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database
Ther Adv Neurol Disord
.
2024 Sep 12:17:17562864241276847.
doi: 10.1177/17562864241276847.
eCollection 2024.
Authors
Charles Khouri
1
2
,
Alex Hlavaty
3
2
,
Bruno Revol
3
2
,
Francesco Salvo
4
5
,
Emanuel Raschi
6
Affiliations
1
Pharmacovigilance Unit, Grenoble Alpes University Hospital, Université Grenoble Alpes, F-38000 Grenoble, France.
2
HP2, Inserm U1300, Université Grenoble Alpes, Grenoble, France.
3
Pharmacovigilance Unit, Grenoble Alpes University Hospital, Université Grenoble Alpes, Grenoble, France.
4
INSERM, BPH, Team AHeaD, U1219, Université de Bordeaux, Bordeaux, France.
5
Service de Pharmacologie Médicale, CHU de Bordeaux, INSERM, U1219, Bordeaux, France.
6
Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
PMID:
39290528
PMCID:
PMC11406657
DOI:
10.1177/17562864241276847
No abstract available
Keywords:
disproportionality analysis; drug repurposing; pharmacovigilance.